Ocrelizumab for psychosis linked to an overactive immune system
Treatments studied
Part of Mental health clinical trials.
This Phase 1/2 study tests ocrelizumab, a medicine that affects parts of the immune system, to see if it can improve psychosis symptoms in people with schizophrenia-spectrum disorders. It’s mainly for younger adults with ongoing psychosis and evidence that the symptoms began early in life, with certain infection/vaccine safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 35 years old (any sex).
- You have an ongoing psychotic disorder for at least 6 months that fits schizophrenia-spectrum criteria.
- Your symptom scores are high enough (a total PANSS of 60 or more, and positive symptoms score 4+ on at least two areas).
- Your school performance was normal at least until age 15, and you did not have psychiatric symptoms before age 15.
- If you take antipsychotic medicine, your dose hasn’t changed within the last 2 weeks before the main symptom check.
- You must be able to agree to the study (consent) or, if needed, assent, and complete study testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
This trial is testing a new medication that may reduce inflammation in the brain for people with schizophrenia. It focuses on those who have a specific immune marker, which might mean the medication could help with symptoms.
This study looks at how immune system health relates to brain changes in people with schizophrenia. It uses brain imaging and electrical activity tests to understand these connections.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.